Fig. 3From: Preclinical studies of toxicity and anti-cholangiocarcinoma activity of the standardized capsule formulation of Atractylodes lancea (Thunb.) DCSurvival time of the CCA-xenografted nude mice following treatment with CMC-AL at high-, medium-, and low-dose levels (5000, 3000 and 1000 mg/kg body weight, respectively), cisplatin (reference control: 40 mg/kg body weight) and untreated controlBack to article page